[Ip-health] Livemint & The Wall Street Journal: Cipla may put patent for new HIV drug in open access pool: Cipla may put patent for new HIV drug in open access pool
thiru at keionline.org
Tue Mar 11 00:24:44 PDT 2014
PUBLISHED: MON, MAR 10 2014. 11 37 PM IST*
*Cipla may put patent for new HIV drug in open access poolCipla says
product under development, doesn't have a time frame for completion as
*Mumbai:* Cipla Ltd
which competed with multinational drug firms by cutting HIV treatment cost
to a fraction of the prevailing rate, is hoping to make a similar impact
with a new four-drug combination to treat HIV/AIDS in infants and children.
The drug is in the advanced stage of development.
The Indian firm led by Y.K.
which will own the intellectual property rights of the first-line
antiretroviral (ARV) combination therapy, plans to put the technology in a
free access patent pool, two company executives said, requesting anonymity.
"This will not only make the drugs free from an otherwise monopolistic
regime but also help other companies to access the technology to come into
the market," one of them said.
The first such open access platform for HIV/AIDS treatment was created in
2010 with the creation of Medicines Patent Pool (MPP), an organization
backed by the United Nations that offered a public health-driven business
model to lower the prices of HIV medicines. MPP also facilitates the
development of better-adapted HIV medicines in developing countries.
Drug makers, including ViiV
a joint venture owned byGlaxoSmithKline
, Pfizer Inc. <http://www.livemint.com/Search/Link/Keyword/Pfizer%20Inc.>
and Shionogi Inc.<http://www.livemint.com/Search/Link/Keyword/Shionogi%20Inc.>,
and US drug makersBristol-Myers Squibb
and Gilead Sciences<http://www.livemint.com/Search/Link/Keyword/Gilead%20Sciences>
signed partnerships in this initiative with MPP. Certain HIV drugs
developed by these firms are licensed to MPP to be manufactured in selected
"It is too early to say the route that
choose to make this technology, which is path-breaking, into the open
access pool and for how many markets," said the first executive cited
Cipla had in 2012 announced a new collaboration with the Drugs for
Neglected Diseases initiative (DNDi), a not-for-profit research and
development organization working to deliver new treatments for neglected
diseases, to develop and produce an improved first-line ARV combination
therapy specifically adapted to meet the treatment needs of infants and
toddlers living with HIV/AIDS.
Once delivered, this new paediatric ARV combination could help accelerate
the provision of care to the world's youngest children living with
HIV/AIDS, who are at very high risk of dying without treatment.
With the four-in-one combination, the firm is trying to develop a
combination of ARV drugs such as Abacavir, Lamivudine, Lopinavir and
Ritonavir into a formulation that is best suited to children under 15 years
"This is going to be something very novel in the world and the major
research project in this direction at present globally, as the delivery
method, taste and easy-to-use elements are very critical in case of
children's therapy," Cipla's chief medical officer Jaideep A.
"The product is under development and progressing, though we don't have a
time frame for the completion as yet," said Gogtay, who declined to share
details about the intellectual property ownership and future plans of the
company in this regard.
More information about the Ip-health